While a variety of mutations may function as MRD markers in AML [14,15,16,17], NPM1 mutation-based MRD remains the most accepted MRD method and has been included in the algorithms for consolidating FLT3-ITD mutated patients [18,19,20]. This evidence concerns the gene FLT3 and acute myeloid leukemia.